Microbial diversity affects whether a tumor grows, leads to inflammation, develops immune escape mechanisms, or develops therapeutic resistance, said an internal medicine specialist.
A comprehensive study exploring NSCLC subgroup responses to immunotherapy may help determine which patients are less likely to benefit from these agents.
"We are seeing some truly surprising response rates and progression-free survival data," says chairman of Unicancer and general director of the Léon Bérard Center in France.